OMH Osmetech

    RNS Number : 1193L
  Osmetech PLC
  05 January 2009
   

    5 January 2009
    Disclosure of Significant Shareholdings

    Osmetech PLC ("Osmetech" or "the Company") (AIM:OMH) announces that it was notified between 23 December 2008 and 2 January 2009 of the
following changes in shareholdings of ordinary 0.1p shares pursuant to the placing announced on 22 December 2008:

    
1.   Efficacy Capital Ltd has increased its shareholding in Osmetech from 125,822,641 to 291,457,742 shares, representing 32.69% of the
Company*s issued share capital. The shareholding is held in two entities:
�      Efficacy Biotech Master Fund which holds 288,487,742 shares representing 32.36% of Company*s issued share capital.
�      FMG Special Opportunity Fund which holds 2,970,000 shares representing 0.33% of Company*s issued share capital.
 
2.   Gartmore Investment Limited has increased its shareholding in Osmetech from 74,047,430 to 166,446,397 shares, representing 18.67% of
the Company*s issued share capital.
 
3.   Polar Capital Healthcare Opportunities Fund has increased its shareholding in Osmetech from 24,800,660 to 66,951,936 shares,
representing 7.51% of the Company*s issued share capital.
 
 
    The total number of issued ordinary 0.1p shares is 891,607,157. Osmetech does not hold any ordinary shares in Treasury. Therefore, the
total number of voting rights in Osmetech is 891,607,157.



    For further information:

 Osmetech plc:                       +44 (0) 20 7849 6027
 James White, Chief Executive
 David Sandilands, Finance Director

 Madano Partnership:                 +44 (0) 207 593 4000
 Mark Way
 Graham Moonie
                                      
 Canaccord Adams Limited:            +44 (0) 20 7050 6500
 Robert Finlay
 Henry Fitzgerald-O'Connor


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
HOLSSDFIISUSELF

Osmetech (LSE:OMH)
Historical Stock Chart
From Feb 2025 to Mar 2025

Osmetech (LSE:OMH)
Historical Stock Chart
From Mar 2024 to Mar 2025